Cleminorexton (INNTooltip International Nonproprietary Name; former developmental code name ORX750) is an orexin OX2 receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia. It is taken orally. The drug was originated by Orexia, was subsequently developed by Centessa Pharmaceuticals, and is now being developed by Eli Lilly and Company. As of November 2025, it is in phase 2 clinical trials for narcolepsy and idiopathic hypersomnia.
See also List of investigational narcolepsy and hypersomnia drugs
References